Mammogram Service Mamotest Arrives in Mexico
The Argentinian Mamotest is providing the latest-generation mammography units in Metepec, State of Mexico, through alliances with the Mexican Hospital Council and Reina Madre women’s clinics. The digital platform aims to fight breast cancer in the country by offering citizens access to more effective and timely detections.
Latin America has one of the highest mortality rates for breast cancer in the world due to a lack of timely, life-saving diagnostics, according to the World Health Organization (WHO). By detecting breast cancer at its early stages, chances of survival rise to a staggering 98 percent. In Mexico, access to high quality diagnostics is harder to find, making it one of the countries in Latin America where this type of cancer takes the longest to detect. Usually, breast cancer among Mexicans is detected in its third or fourth stages, rather than the ideal first stage.
Mamotest, selected by the UN as one of the four organizations changing the first level healthcare sector globally, supplies the latest-generation mammography units to places that lack access to this type of cutting-edge technology. Mammograms are then administered and uploaded to a cloud where medical specialists can examine and provide results to patients within 24 hours.
Mamotest’s allied with VARA, an AI developer used by Germany’s public health system, to help the diagnosis be as accurate as possible. VARA aids medical professionals by providing alerts on images that the doctor may have missed, ensuring all cases of breast cancer are correctly diagnosed. The company claims the incorporation of this technology makes Mamotest one of the most accurate diagnostic systems in the world.
“We are very happy to arrive in Mexico with a solution that will allow thousands of lives to be saved. In Argentina we met the people of Merck & Co. Inc who invested in Mamotest, which allowed us to look ahead and Mexico was the first choice,” said Guillermo Pepe, Founder and Director, Mamotest. The company received US$1.6 million from Merck & Co. Inc, known outside of the US as Merck Sharp & Dohme (MSD), to expand its services and technologies.
“For us, as a pharmaceutical company, aside from direct business it is important to make impactful investments, socially and financially, we look for geographic opportunities such as in Mexico. Mamotest represents exactly what we are looking for,” said Kenneth Gustavsen, Executive Director of Global Business, MSD.
This is the first of 50 centers Mamotest plans to open across the country during the next 24 months. Next month, Mamotest will reach Pachuca, Hidalgo and Veracruz thanks to the funding the company has been able to secure thus far.